Cite
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials.
MLA
Lambrechts D, et al. “VEGF Pathway Genetic Variants as Biomarkers of Treatment Outcome with Bevacizumab: An Analysis of Data from the AViTA and AVOREN Randomised Trials.” Lancet Oncology, vol. 13, no. 7, July 2012, pp. 724–33. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=asx&AN=104472515&authtype=sso&custid=ns315887.
APA
Lambrechts D, Claes B, Delmar P, Reumers J, Mazzone M, Yesilyurt BT, Devlieger R, Verslype C, Tejpar S, Wildiers H, de Haas S, Carmeliet P, Scherer SJ, & Van Cutsem E. (2012). VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncology, 13(7), 724–733.
Chicago
Lambrechts D, Claes B, Delmar P, Reumers J, Mazzone M, Yesilyurt BT, Devlieger R, et al. 2012. “VEGF Pathway Genetic Variants as Biomarkers of Treatment Outcome with Bevacizumab: An Analysis of Data from the AViTA and AVOREN Randomised Trials.” Lancet Oncology 13 (7): 724–33. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=asx&AN=104472515&authtype=sso&custid=ns315887.